What does NICE say about semaglutide for weight management?

What exactly did NICE decide in TA875?

NICE's appraisal of semaglutide for weight management concluded that Wegovy is clinically effective and cost-effective enough to recommend on the NHS, but with clear conditions. The full recommendation in NICE technology appraisal TA875 states that semaglutide should only be offered within a specialist weight management service, one that provides multidisciplinary support including dietary advice, physical activity guidance and psychological input. This isn't a GP prescription in the ordinary sense; it sits within services sometimes called tier 3 or tier 4 weight management.

Treatment is also capped at two years. NICE's rationale is that the medicine supports a period of structured weight loss, but long-term prescribing without a defined endpoint was considered outside the cost-effective range for routine NHS use. If a patient has not lost at least 5% of their body weight after six months at the maintenance dose, NICE recommends stopping treatment and reviewing the plan.

The appraisal drew on evidence from the STEP 1 trial, which found an average weight reduction of around 15% over 68 weeks at the semaglutide 2.4mg maintenance dose, data published in the New England Journal of Medicine. That figure underpinned NICE's confidence in the medicine's effectiveness.

Who does the NICE guidance say can access semaglutide on the NHS?

The BMI threshold in TA875 is 35 or above, with at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. People with a BMI of 30–34.9 may also be considered if they meet the criteria for specialist referral under the relevant NHS pathways.

Ethnic background matters here. For people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean heritage, NHS guidance applies thresholds that are 2.5 kg/m² lower, so 32.5 instead of 35, and 27.5–32.4 instead of 30–34.9. This adjustment reflects evidence that weight-related health risks tend to occur at lower BMI values in these populations.

Even meeting all the numerical criteria does not guarantee access. NHS waiting lists for specialist weight management services are long in many areas, and service availability varies considerably by region. The NHS England weight management injections page sets out the access framework and what wraparound care should include.

It is also worth reading what NICE says about Wegovy's NHS recommendation separately, as it covers the service requirements and monitoring expectations in detail.

How does the NICE semaglutide guidance compare with the private prescription route?

Private prescriptions for semaglutide follow the medicine's licensed criteria rather than the NICE commissioning conditions. The Wegovy licence covers adults with a BMI of at least 30, or at least 27 where a weight-related condition is present, a wider group than NICE's NHS threshold of 35, and treatment typically begins at the semaglutide 0.25mg starting dose before being titrated upward. There is no two-year cap written into the licence; duration is a clinical decision between prescriber and patient, reviewed at each repeat.

There is no specialist-service requirement for a private prescription either. A GPhC-registered independent prescriber can assess suitability, provided the clinical review is thorough. At nume's pharmacy, every consultation is personally read by a prescriber (never processed by an algorithm) on the same day it is submitted. That includes checking medical history, current medicines and any contraindications before any treatment is approved.

If you want to understand more about semaglutide's evidence base for weight loss before deciding whether to ask about a private prescription, that context is worth having first. The cost of private treatment is also a fair consideration, our Wegovy price comparison guide explains what to look for in a private quote and what a legitimate price should include.

Are there situations where the NICE guidance does not apply?

TA875 is an NHS commissioning recommendation, it tells NHS services when they can fund semaglutide. It does not restrict a private prescriber from prescribing it to someone with a BMI of, say, 31 with hypertension, even though that person would not qualify for NHS funding under TA875. The licensed indication is the legal threshold for prescribing; NICE guidance governs NHS budget decisions, not the medicine's legality.

Scotland, Wales and Northern Ireland have their own processes. NHS Scotland commissions medicines through the Scottish Medicines Consortium, and access pathways differ. If your query is specifically about semaglutide's licensing and availability in devolved nations, the picture varies enough to check locally.

One practical note: semaglutide for weight loss is a prescription-only medicine. A prescriber (not a website, not an automated quiz) decides clinical suitability. If you're ready to see whether you meet the criteria for a private prescription, checking your eligibility with our clinical team is the straightforward next step.